Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
Authors
Keywords
-
Journal
Frontiers in Neurology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-05-28
DOI
10.3389/fneur.2020.00417
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
- (2020) Stewart J Tepper et al. CEPHALALGIA
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab: from scientific evidence to clinical practice—the first Italian real-life data
- (2019) Piero Barbanti et al. NEUROLOGICAL SCIENCES
- Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies
- (2019) Andrea Negro et al. Expert Review of Neurotherapeutics
- The American Headache Society’s Position Statement on Integrating New Migraine Treatments into Clinical Practice – Comments
- (2019) James A. Charles et al. HEADACHE
- Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
- (2019) Bianca Raffaelli et al. JOURNAL OF HEADACHE AND PAIN
- 074 Early australian experience with erenumab for chronic migraine
- (2019) Shuli Cheng et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Current and emerging evidence-based treatment options in chronic migraine: a narrative review
- (2019) Elio Clemente Agostoni et al. JOURNAL OF HEADACHE AND PAIN
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
- (2019) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double‐blind studies
- (2019) J. Ailani et al. EUROPEAN JOURNAL OF NEUROLOGY
- Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
- (2018) Messoud Ashina et al. CEPHALALGIA
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- Therapie der chronischen Migräne mit Botulinumneurotoxin A
- (2018) R. Ruscheweyh et al. NERVENARZT
- Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
- (2018) Casper Emil Christensen et al. JOURNAL OF HEADACHE AND PAIN
- Early onset of efficacy with erenumab in patients with episodic and chronic migraine
- (2018) Todd Schwedt et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study
- (2017) Clara Domínguez et al. HEADACHE
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
- (2017) Simona Guerzoni et al. Frontiers in Neurology
- Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab
- (2017) Maria Giamberardino et al. Journal of Pain Research
- Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
- (2016) Zsolt Hepp et al. CEPHALALGIA
- Adherence to oral migraine-preventive medications among patients with chronic migraine
- (2014) Zsolt Hepp et al. CEPHALALGIA
- Insights Into the Mechanism of OnabotulinumtoxinA in Chronic Migraine
- (2011) Paul L. Durham et al. HEADACHE
- OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program
- (2010) David W. Dodick et al. HEADACHE
- Guidelines for Controlled Trials of Prophylactic Treatment of Chronic Migraine in Adults
- (2008) S Silberstein et al. CEPHALALGIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started